Fig. 1: Oral administration of reovirus shows potent antitumor efficacy in a multifocal tumor model.

Mice were subcutaneously implanted with CT26 or MC38 tumor cells in single (A–D) or multifocal (E–H) lesions and treated with RC402 (R) and/or αPD-1 (PD1). A Schematic diagram of the treatment schedule in single tumor-bearing mice. Arrows indicate treatments. B Comparison of tumor growth in single tumor-bearing mice treated with phosphate buffered saline (PBS, n = 5), intratumoral (IT) RC402 (n = 6), or oral RC402 (n = 6). C Comparison of tumor growth suppression in single tumor-bearing mice. Each bar indicates the % change in each tumor volume compared to the mean of control tumor volumes at the end of treatment. D Comparison of MC38 tumor growth in single tumor-bearing mice treated with PBS, IT RC402, or oral RC402 (n = 6 per group). E Schematic diagram of the treatment schedule in multifocal tumor-bearing mice. The tumor in the right upper quadrant was labeled as tumor 1, and others are labeled as 2, 3, and 4 in a counterclockwise direction. Mice were treated with PBS, IT RC402, or oral RC402, and/or αPD-1. Arrows indicate treatments. Comparison of tumor growth suppression in multifocal tumor-bearing mice treated with IT RC402 (F) or oral RC402 (G) (n = 5 per group). Each bar indicates the % change in each tumor volume compared to the mean of control tumor volumes at the end of treatment. H Comparison of the sum of all tumor volumes per mouse. Overall tumor volume was calculated by summing the volume of every tumor per mouse and normalizing it to the mean overall tumor volume of the control group. Dotter line indicates the mean of overall tumor burden in control group (n = 5 per group). Data are pooled from two independent experiments. Values are expressed as the mean ± standard deviation (SD). Two-tailed Student’s t test and ANOVA with Tukey post-hoc test were used. Source data are provided as a Source Data file.